Anti-CD20− / anti-BAFF bispecific antibodies
US9951146B2 · kind B2 · utility
0Cited by
13References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 24, 2016 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | Mar 24, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.